A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Launched by HOFFMANN-LA ROCHE · Feb 11, 2008
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, 18-65 years of age;
- • HBsAg positive, HBeAg positive and anti-HBe negative for at least 6 months, anti-HBs negative;
- • absence of cirrhosis confirmed by liver biopsy in previous 12 months.
- Exclusion Criteria:
- • previous treatment for chronic hepatitis B within previous 6 months;
- • antiviral, anti-neoplastic or immunomodulatory treatment in previous 6 months;
- • co-infection with active hepatitis A, hepatitis C, hepatitis D or HIV;
- • history or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Beijing, , China
Hangzhou, , China
Shanghai, , China
Xi'an, , China
Zhengzhou, , China
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials